Bifalgorithm post · Cancer in 2026: How Immunotherapy Is Reshaping the Odds · Immunotherapy Is Helping Rewrite Survival Curves

Melanoma Progress

Melanoma Progress (Cancer in 2026: How Immunotherapy Is Reshaping the Odds · Immunotherapy Is Helping Rewrite Survival Curves) — "“When we look at metastatic m…

Ideas in this flowchart

Metastatic melanoma survival improvement reflects immunotherapy breakthroughs
Survival improved from 16% to 35% in 25 years
Immune checkpoint inhibitors directly contributed to this improvement
Examples include anti-PD-1 and anti-CTLA-4 therapies
The Cancer Research Institute championed these breakthroughs for decades
CRI supported the fundamental science behind immunotherapy
That science made immunotherapies a reality
Statement by Antoni Ribas, MD, PhD, a UCLA professor and CRI Scientific Advisory Council member

Bifalgorithm

Feed/

Melanoma Progress

No cover

Channel

Cancer in 2026: How Immunotherapy Is Reshaping the Odds

1 page

USR292600b83e2a

Ebook2w

"“When we look at metastatic melanoma survival improving from 16% to 35% in just 25 years, we’re witnessing the direct impact of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies. These are the breakthroughs that the Cancer Research Institute has championed for decades — supporting the fundamental science that made immunotherapies a reality.”– Antoni Ribas, MD, PhD, Professor at UCLA and CRI Scientific Advisory Council member"

Flowchart preview

👍

0 comments0 shares